News: stock, crypto, macro, education

Boston Scientific Reports Robust Second Quarter 2024 Results

Boston Scientific Reports Robust Second Quarter 2024 Results

Marlborough, Mass., July 24, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced its financial results for the second quarter of 2024, showcasing significant growth and strong financial performance.

Financial Highlights:

  • Net Sales: $4.120 billion, a 14.5% increase on a reported basis, 16.1% on an operational basis, and 14.7% on an organic basis compared to Q2 2023.
  • GAAP Net Income: $324 million, or $0.22 per share, up from $261 million, or $0.18 per share, in Q2 2023.
  • Adjusted EPS: $0.62, compared to $0.53 in the prior year.

Mike Mahoney, CEO of Boston Scientific, stated, "We delivered a quarter marked by exceptional performance, reflecting our global team's relentless pursuit of innovation supported by strong clinical evidence and strategic investments."

Segment and Regional Performance:

  • MedSurg Segment:

    • Endoscopy: 7.1% reported, 8.4% operational, and 7.9% organic growth.
    • Urology: 8.2% reported, 9.1% operational, and 9.1% organic growth.
    • Neuromodulation: 15.5% reported, 16.2% operational, and 3.7% organic growth.
  • Cardiovascular Segment:

    • Cardiology: 20.1% reported, 22.0% operational, and 22.0% organic growth.
    • Peripheral Interventions: 10.2% reported, 12.3% operational, and 9.4% organic growth.
  • Regional Growth:

    • U.S.: 16.9% reported and operational growth.
    • EMEA: 13.7% reported, 16.1% operational growth.
    • APAC: 7.0% reported, 13.2% operational growth.
    • LACA: 15.3% reported, 15.7% operational growth.
    • Emerging Markets: 14.8% reported, 19.3% operational growth.

Key Developments:

  • Product Approvals and Launches:

    • NMPA approval in China for FARAPULSE™ Pulsed Field Ablation (PFA) System.
    • U.S. launch of the AGENT™ Drug-Coated Balloon.
    • NMPA approval for AGENT™ Drug-Coated Balloon in China.
  • Clinical Data:

    • Positive outcomes from the pivotal ADVENT clinical trial and FARADISE registry.
    • Favorable results from the MODULAR ATP clinical trial of the Modular CRM (mCRM™) System.
    • Significant improvements in vertebrogenic pain reported at the 2024 American Society of Pain & Neuroscience meeting.
  • Strategic Acquisition:

    • Announced agreement to acquire Silk Road Medical, Inc., enhancing the company's capabilities in stroke prevention.
  • Leadership and Governance:

    • Dr. Cheryl Pegus elected to the board of directors, bringing extensive experience in health and wellness.

Full Year and Third Quarter 2024 Guidance:

  • Full Year 2024:

    • Net Sales Growth: 13.5% to 14.5% on a reported basis, 13% to 14% on an organic basis.
    • GAAP EPS: $1.34 to $1.38.
    • Adjusted EPS: $2.38 to $2.42.
  • Third Quarter 2024:

    • Net Sales Growth: 13% to 15% on both reported and organic basis.
    • GAAP EPS: $0.36 to $0.38.
    • Adjusted EPS: $0.57 to $0.59.

 

Source: BSX

More articles